Abstract
Donohue syndrome (DS) is a severe form of congenital insulin resistance due to mutation(s) in the insulin receptor (INSR) gene. Given the similarities between insulin and insulin-like growth factor 1 (IGF-1) receptors, recombinant human IGF-1 (rhIGF-1) has been used to treat severe insulin resistance due to INSR mutation(s). Traditional subcutaneous therapy may be limited by the shortened IGF-1 half-life in these patients. We report the case of a female with molecularly confirmed DS treated with continuous rhIGF-1 therapy via an insulin pump. With treatment, the patient's hemoglobin A1c decreased from 9.8% to 8.8%, and her weight increased by 0.8 kg. Development of an ovarian tumor complicated her course, but it was unclear whether this was related to rhIGF-1 therapy. Limited treatment options exist for patients with DS. The use of continuous rhIGF-1 via an insulin pump may be a viable option, although further experience is needed to establish safety and efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 1237-1241 |
| Number of pages | 5 |
| Journal | Journal of Pediatric Endocrinology and Metabolism |
| Volume | 27 |
| Issue number | 11-12 |
| Early online date | 5 Aug 2014 |
| DOIs | |
| Publication status | Published - 1 Nov 2014 |
Keywords / Materials (for Non-textual outputs)
- Donohue syndrome
- insulin infusion systems
- insulin resistance
- insulin-like growth factor
Fingerprint
Dive into the research topics of 'Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver